Biologics Hospitals Top Stories OssDsign awarded long-term agreement with Premier, Inc. byJosh SandbergApril 2, 2024
Biologics Spine OssDsign appoints Tom Buckland as Chief Technical Officer byJosh SandbergFebruary 29, 2024
Regulatory Spine Karolinska Development’s portfolio company OssDsign has received FDA clearance for a new major indication byJosh SandbergSeptember 19, 2023
Biologics Spine 2,000 patients treated with OssDsign® Catalyst in the U.S. byJosh SandbergSeptember 13, 2023
Spine OssDsign surpasses 200 patients in its prospective spinal fusion registry PROPEL byJosh SandbergAugust 17, 2023
Biologics Spine Karolinska Development’s portfolio company OssDsign has published a case report from the TOP FUSION study in a scientific journal byJosh SandbergJanuary 4, 2023
Spine Karolinska Development’s portfolio company OssDsign completes patient enrollment to the TOP FUSION study byChris StewartApril 25, 2022
